End-of-day quote
Other stock markets
|
||
- EUR | - |
|
06-27 | GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650 | MT |
06-27 | GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study | DJ |
Business Summary
The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 61 | 12/01/21 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 13/12/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 30/04/23 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 10/11/20 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 12/01/21 |
Michael Breen
CEO | Chief Executive Officer | 61 | 12/01/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 96,230 | 0 | 0 | 89.34 % |
Stock B | 1 | 2,156,651 | 2,012,830 ( 93.33 %) | 0 |
Company contact information
GT Biopharma, Inc.
8000 Marina Boulevard Suite 100
94005, Brisbane
+415 919 4040
http://www.gtbiopharma.com![address Oxis International](https://cdn.zonebourse.com/static/address/5422.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+57.15% | 848B | |
+31.64% | 627B | |
-0.52% | 363B | |
+15.43% | 318B | |
+12.47% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.27% | 179B | |
+3.23% | 167B |
- Stock Market
- Equities
- GTBP Stock
- Stock
- Company Oxis International